The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
News  >  

Targeted Top 5: Oncology News This Week

Danielle Ternyila
Published Online:1:24 PM, Fri August 17, 2018
Each week, Targeted Oncology reports current advancements in cancer research, including interviews with oncology experts, conference coverage, clinical trial results, and the most recent approvals. Check out our weekly roundup below of the biggest news in oncology that we shared this week.
Follow the links below in our infographic to check out the full story.
This week, we heard from several hematology experts on the latest updates in their field, including Andre Goy, MD, who discussed some of the recent progress that has been made in clinical trials for mantle cell lymphoma (MCL) and how that research can be better translated to the real world. In our interview with Susan M. O’Brien, MD, she shed light on some of the latest intriguing data in the treatment of chronic lymphocytic leukemia (CLL) and what these updates means for physicians and patients. 
In a video interview, David Sallman, MD, discussed recent data from a trial combining APR-246 and azacitidine (Vidaza) in patients with TP53-mutant myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
Additionally, Sanjiv S. Agarwala, MD, shared his insights on a trial investigating pembrolizumab (Keytruda) with entinostat in a cohort of patients with melanoma.
Based on 2 non–small cell lung cancer (NSCLC) case studies, Kartik Konduri, MD, discussed the treatment considerations he would make, and also discussed the new standard of care in NSCLC, immunotherapy combined with chemotherapy.
Finally, Shilpa Gupta, MD, discussed the tolerability and safety of pembrolizumab and bevacizumab (Avastin) in renal cell carcinoma, as well as the future of bladder cancer treatment in the neoadjuvant setting.
Use the links above in our infographic to access the full stories with these experts in cancer research.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.